Wealthcare Capital Management LLC makes new investment in Johnson & Johnson (NYSE: JNJ)


Wealthcare Capital Management LLC acquired a new position in shares of Johnson & Johnson (NYSE: JNJ – Get Rating) in the 1st quarter, according to its latest 13F filing with the Securities and Exchange Commission (SEC). The company acquired 1,567 shares of the company’s stock worth approximately $ 278,000.

Other hedge funds have also recently changed their holdings in the company. Magnolia Capital Management Ltd. increased its stake in Johnson & Johnson by 0.5% in the first quarter. Magnolia Capital Management Ltd. now owns 11,162 shares of the company’s stock worth $ 1,978,000 after purchasing an additional 55 shares during the period. Capital Investment Counsel Inc increased its stake in Johnson & Johnson by 0.8% in the fourth quarter. Capital Investment Counsel Inc now owns 7,796 shares of the company’s shares worth $ 1,334,000 after purchasing an additional 59 shares during the period. Beaton Management Co. Inc. increased its stake in Johnson & Johnson by 0.3% in the fourth quarter. Beaton Management Co. Inc. now owns 22,250 shares of the company’s stock worth $ 3,806,000 after purchasing an additional 60 shares during the period. Corsicana & Co. increased its stake in Johnson & Johnson by 0.4% in the first quarter. Corsicana & Co. now owns 15,553 shares of the company’s stock worth $ 2,756,000 after purchasing an additional 60 shares during the period. Finally, Iron Horse Wealth Management LLC increased its stake in Johnson & Johnson by 29.9% in the fourth quarter. Iron Horse Wealth Management LLC already owns 265 shares of the company’s stock worth $ 45,000 after purchasing an additional 61 shares during the period. Hedge funds and other institutional investors own 68.78% of the company’s shares.

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of the shares in a deal on Friday, June 10th. The shares were sold at an average price of $ 173.00 for a total transaction of $ 6,920,000.00. Following the completion of the sale, the executive vice president now owns 71,311 shares of the company’s stock worth approximately $ 12,336,803. The transaction is disclosed in legal documents in the Securities and Exchange Commission, which is available through the SEC website. Also, insider William Hate sold 29,699 shares of the company’s shares in a deal on Thursday, April 21. The shares were sold at an average price of $ 183.58, for a total transaction of $ 5,452,142.42. Following the completion of the sale, the insider now directly owns 80,236 shares of the company worth $ 14,729,724.88. The disclosure for this sale can be found here. Over the past ninety days, insiders have sold 78,161 shares of the company worth $ 13,895,302. 0.35% of the shares are owned by corporate insiders.

Several research analysts recently commented on the shares. Sanford C. Bernstein downgraded Johnson & Johnson shares from a “superior” rating to a “market performance” rating and raised their target price for the shares from $ 180.00 to $ 183.00 in a report on Wednesday, March 16. Morgan Stanley lowered its price target for Johnson & Johnson shares from $ 175.00 to $ 173.00 and set an “equal weight” rating for the shares in a research note on Wednesday, April 6. Citigroup lowered its price target for Johnson & Johnson shares from $ 210.00 to $ 205.00 in a research note on Tuesday, May 17. Daiwa Capital Markets began covering shares of Johnson & Johnson in a research note on Wednesday. They issued a rating of “superior” to the shares. Finally, StockNews.com raised Johnson & Johnson shares from a buy rating to a strong buy rating in a survey note on Tuesday, May 17th. Four investment analysts rated the shares with a hold rating, six gave a buy rating and one gave a strong buy rating for the company’s shares. According to MarketBeat.com, the company currently has an average “Moderate Buying” rating and a consensus target price of $ 190.50.

Shares of Johnson & Johnson opened at $ 182.29 on Friday. Johnson & Johnson has a fifty-two weekly low of $ 155.72 and a fifty-two week high of $ 186.69. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39 and a fast ratio of 1.14. The company has a market capitalization of $ 479.68 billion, a P / E ratio of $ 24.57, a P / E / G ratio of $ 3.55 and a beta ratio of 0.66. The company’s 50-day moving average price is $ 177.70, and its 200-day moving average is $ 173.40.

Johnson & Johnson (NYSE: JNJ – Get Rating) last released its earnings results on Tuesday, April 19th. The company reported earnings of $ 2.67 per share for the quarter, beating analysts’ consensus estimates of $ 2.60 by $ 0.07. Johnson & Johnson had a net profit of 20.90% and a return on equity of 36.59%. The company had revenue of $ 23.43 billion for the quarter, compared to analysts’ estimates of $ 23.62 billion. In the same quarter last year, the business reported $ 2.59 earnings per share. The company’s quarterly revenues increased by 5.0% on an annual basis. On average, analysts expect Johnson & Johnson to report 10.23 earnings per share for the current year.

The company also recently unveiled a three-month dividend that was paid on Tuesday (June 7th). The record investors on Tuesday, May 24, received a dividend of $ 1.13. That’s a boost from Johnson & Johnson’s previous quarterly $ 1.06 dividend. The date of the former dividend on this dividend was Monday, May 23. This represents a $ 4.52 annual dividend and a dividend yield of 2.48%. Johnson & Johnson’s payout ratio is currently 60.92%.

About Johnson & Johnson (Get a rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells a variety of healthcare products worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral hygiene products with the brand LISTERINE; skin health and beauty products under AVEENO, CLEAN & CLEAR, DR.

Selected articles

Want to see what other hedge funds hold JNJ? Visit HoldingsChannel.com to get the latest 13F requests and domestic deals for Johnson & Johnson (NYSE: JNJ – Get rating).

Institutional ownership by quarter for Johnson & Johnson (NYSE: JNJ)



Receive news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a brief daily summary of the latest news and analyst ratings for Johnson & Johnson and related companies with the FREE Daily Newsletter on MarketBeat.com.

Leave a Comment